GLP1R and liver dysplastic nodule: The data strongly suggests that increased GLP-1 activity via administration of GLP-1R agonists or DPP-4i may reduce main molecular mechanisms underlying DN, such as oxidative stress, inflammation, endothelial function, and cellular death dependent on apoptosis and/or fibrosis (Table 2).